Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week …

…, M Lorenz, J Roehmel, W Gleiber… - The Lancet …, 2022 - thelancet.com
Background Elexacaftor plus tezacaftor plus ivacaftor is a triple-combination cystic fibrosis
transmembrane conductance regulator (CFTR) modulator regimen shown to be generally safe …

Liver fibrosis and metabolic alterations in adults with alpha-1-antitrypsin deficiency caused by the Pi* ZZ mutation

…, J van Helden, E Yagmur, D Bzdok, J Stolk, W Gleiber… - Gastroenterology, 2019 - Elsevier
Background & Aims Alpha-1 antitrypsin deficiency (AATD) is among the most common genetic
disorders. Severe AATD is caused by a homozygous mutation in the SERPINA1 gene that …

[HTML][HTML] Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide …

…, W Weichert, M Heilmann, P Sadjadian, W Gleiber… - Lung Cancer, 2021 - Elsevier
Objectives An increasing number of treatment-determining biomarkers has been identified
in non-small cell lung cancer (NSCLC) and molecular testing is recommended to enable …

[HTML][HTML] Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis

…, K Feifel, E Herrmann, T Poynard, W Gleiber… - Journal of Cystic …, 2013 - Elsevier
Background Patients with cystic fibrosis (CF) have a relevant morbidity and mortality caused
by CF-related liver-disease. While transient elastography (TE) is an established …

Association of disease progression with health-related quality of life among adults with breast, lung, pancreatic, and colorectal cancer

…, U Martens, A Welt, V Hagen, W Gleiber… - JAMA network …, 2020 - jamanetwork.com
Importance Mortality, morbidity, and health-related quality of life (HRQoL) are patient-relevant
end points generally considered in the early benefit assessments of new cancer treatments…

Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del …

…, C Koerner-Rettberg, D Staab, W Gleiber… - The Lancet …, 2021 - thelancet.com
Background Tezacaftor–ivacaftor is an approved cystic fibrosis transmembrane conductance
regulator (CFTR) modulator shown to be efficacious and generally safe and well tolerated …

[HTML][HTML] Severe asthma standard-of-care background medication reduction with benralizumab: ANDHI in practice substudy

…, D Skowasch, C Taube, T Welte, W Gleiber… - The Journal of Allergy …, 2023 - Elsevier
Background The phase IIIb, randomized, parallel-group, placebo-controlled ANDHI double-blind
(DB) study extended understanding of the efficacy of benralizumab for patients with …

Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung …

C Grohé, W Gleiber, S Haas, C Losem… - Future …, 2019 - Future Medicine
Aim: To assess outcomes in patients with advanced adenocarcinoma non-small-cell lung
cancer who received nintedanib plus docetaxel after progression on prior chemotherapy …

[HTML][HTML] Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis—results of a multicenter, prospective, randomized …

…, B Wiedemann, D Staab, W Gleiber… - Journal of Cystic …, 2016 - Elsevier
Background Chronic rhinosinusitis is a hallmark of Cystic fibrosis (CF) impairing the patients'
quality of life and overall health. However, therapeutic options have not been sufficiently …

[HTML][HTML] Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancer

JA Stratmann, R Lacko, O Ballo, S Shaid, W Gleiber… - PloS One, 2020 - journals.plos.org
Objectives Multidrug-resistant organisms (MDRO) are considered an emerging threat
worldwide. Data covering the clinical impact of MDRO colonization in patients with solid …